// App-Quantinova.ai

THU0379 : REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOLLOWING ONE YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL: 48-WEEK INTERIM RESULTS FROM A 96-WEEK OPEN-LABEL STUDY

Researchers

Presenter

  • I. Van der Horst-Bruinsma

Principal Investigators

  • R. Van Bentum

  • F. Verbraak

  • T. Rath

  • J. Rosenbaum

  • M. Misterska-Skora

  • B. Hoepken

  • O. Irvin-Sellers

  • B. Vanlunen

  • L. Bauer

  • M. Rudwaleit

Medical Centers

  • VU University Medical Center, Amsterdam, Netherlands

  • St Franziskushospital, Muenster, Germany

  • Devers Eye Institute, Portland, United States of America

  • Oregon Health & Science University, Portland, United States of America

  • Wroclaw Medical University, Wroclaw, Poland

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, United States of America

  • Klinikum Bielefeld and Charite, Berlin, Germany

  • Ghent University Hospital, Ghent, Belgium

Locations

  • Netherlands

  • Germany

  • United States

  • Poland

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • IV

Study Id's

  • NCT03020992

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved